Tsuchimoto Kim R's Form 4/A amendment
AmendedMonopar Therapeutics (MNPR) · filed Aug 28, 2026
- Accession no.
- 0001437749-26-029235
- Filed
- Aug 28, 2026, 8:18 PM ET
- Trade date
- Aug 26, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Aug 27, 2026
This filing lists 8 non-derivative transactions and 2 derivative transactions. Open-market sales total $455.6K. It was filed 2 days after the trade.
This amendment replaces 0001437749-26-029116 (filed Aug 27, 2026).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tsuchimoto Kim RCIK 0001333516 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 26, 2026 | Common Stock | MOption exerciseAcquired | +2,055 | $30.00 | +$61,650 | 2,055 | Direct | |
| Aug 26, 2026 | Common Stock | MOption exerciseAcquired | +2,035 | $14.00 | +$28,490 | 4,090 | Direct | |
| Aug 26, 2026 | Common Stock | SSaleDisposed | −485 | $108.83F4 | −$52,782.55 | 3,605 | Direct | |
| Aug 26, 2026 | Common Stock | SSaleDisposed | −615 | $109.56F5 | −$67,379.4 | 2,990 | Direct | |
| Aug 26, 2026 | Common Stock | SSaleDisposed | −700 | $110.65F6 | −$77,455 | 2,290 | Direct | |
| Aug 26, 2026 | Common Stock | SSaleDisposed | −1,098 | $111.84F7 | −$122,800.32 | 1,192 | Direct | |
| Aug 26, 2026 | Common Stock | SSaleDisposed | −602 | $112.93F8 | −$67,983.86 | 590 | Direct | |
| Aug 26, 2026 | Common Stock | SSaleDisposed | −590 | $113.84F9 | −$67,165.6 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 26, 2026 | Common Stock | MOption exerciseAcquired | +2,055 | $0.00 | $0 | 6,165 | Direct | |
| Aug 26, 2026 | Common Stock | MOption exerciseAcquired | +2,035 | $0.00 | $0 | 8,140 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
- F2
On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.
- F3
On February 2, 2022, the reporting person was granted stock options to purchase up to 16,279 shares of common stock. The options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F10
Represents shares held by the Kim R. Tsuchimoto Trust dated October 6, 2015.
Remarks
On August 27, 2026, the reporting person filed a Form 4, which inadvertently omitted two option exercises that were made prior to the reporting person's sale of shares of common stock. Both the option exercises and the sales of common stock were effected pursuant to a Rule 10b5-1 Plan.